REFERENCES
3. Conroy T, Desseigne F, Ychou M, et al.; Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-25.
4. Barreto SG, Maitra A, O’Reilly EM, Sahani D, Zheng R, Yeo CJ. Pancreatic cancer-advances in the last 50 years. World J Surg. 2026;50:2106-15.
5. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418-29.
6. Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719-34.
7. Waddell N, Pajic M, Patch AM, et al.; Australian Pancreatic Cancer Genome Initiative. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495-501.
8. Digiacomo G, Volta F, Garajova I, Balsano R, Cavazzoni A. Biological hallmarks and new therapeutic approaches for the treatment of PDAC. Life. 2021;11:843.
9. Collins MA, Bednar F, Zhang Y, et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest. 2012;122:639-53.
10. Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med. 2022;387:120-31.
11. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371-81.
13. Strickler JH, Satake H, Hollebecque A, et al. First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: a phase I/II study evaluating efficacy and safety. J Clin Oncol. 2022;40:360490.
14. Wang X, Allen S, Blake JF, et al. Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. J Med Chem. 2022;65:3123-33.
15. Adachi Y, Ito K, Hayashi Y, et al. Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer. Clin Cancer Res. 2020;26:5962-73.
16. Hou P, Kapoor A, Zhang Q, et al. Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer. Cancer Discov. 2020;10:1058-77.
17. Hayes TK, Neel NF, Hu C, et al. Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression. Cancer Cell. 2016;29:75-89.
18. Than MT, Dequiedt L, Sor R, et al. Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma. Science. 2026;391:1161-6.
19. Conroy T, Hammel P, Hebbar M, et al.; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395-406.
20. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-703.
21. Abbas AA, Davelaar J, Gai J, et al. Preliminary translational immune and stromal correlates in a randomized phase II trial of pembrolizumab with or without defactinib for resectable pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2023;41:4024.
22. Kessler D, Gmachl M, Mantoulidis A, et al. Drugging an undruggable pocket on KRAS. Proc Natl Acad Sci U S A. 2019;116:15823-9.
23. Kemp SB, Cheng N, Markosyan N, et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 2023;13:298-311.
24. Bekaii-Saab TS, Yaeger R, Spira AI, et al. Adagrasib in advanced solid tumors harboring a KRASG12C mutation. J Clin Oncol. 2023;41:4097-106.
25. Lanman BA, Allen JR, Allen JG, et al. Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. J Med Chem. 2020;63:52-65.
26. Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10:54-71.
27. Mahadevan KK, McAndrews KM, LeBleu VS, et al. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell. 2023;41:1606-20.e8.
28. Hobbs GA, Baker NM, Miermont AM, et al. Atypical KRASG12R mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer. Cancer Discov. 2020;10:104-23.
29. Yadav V, Kashif M, Sharma S, Subbarao N. Development of potent inhibitors against KRAS, its mutant G12R, allosteric and Switch-I/Switch-II site. In Silico Pharmacol. 2025;13:131.
30. Riedl JM, Matsubara H, McNeil R, et al. Emerging landscape of KRAS inhibitors in cancer treatment. Cancer Cell. 2026;44:471-97.
31. Yang X, Zhu X, Han H, et al. Abstract 4379: BPI-572270: an orally bioavailable and highly potent RAS (On) multi tri-complex inhibitor. Cancer Res. 2025;85:4379.
32. Arbour KC, Tawee T, Yaeger R, et al. Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors. Cancer Res. 2025;85:CT019.
33. Spira AI, Papadopoulos KP, Kim DW, et al. Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. J Clin Oncol. 2025;43:724.
34. Lu S, Li Z, Ai X, et al. MA02.07 Efficacy and safety of GFH375 in advanced non-small cell lung cancer patients with KRAS G12D mutation. J Thorac Oncol. 2025;20:S59-60.
35. Zhou A, Li Z, Sun Y, et al. LBA84 Efficacy and safety of GFH375 monotherapy in previously treated advanced KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC). Ann Oncol. 2025;36:S1626.
36. Punekar S, Hong D, Luo J, et al. 6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC). J Thorac Oncol. 2025;20:S10-1.
37. Garrido-Laguna I, Wolpin BM, Park W, et al. Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2025;43:722.
38. Mitsunaga S, Kasamatsu E, Machii K. Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma. Support Care Cancer. 2020;28:5271-9.
39. Khalil MA, Jafri SAA, Zahra Naqvi ME, et al. Impact of cachexia on chemotherapy efficacy and survival in pancreatic cancer: a systematic review and meta-analysis. Cancer Control. 2024;31.
40. Xue JY, Zhao Y, Aronowitz J, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020;577:421-5.
41. Misale S, Fatherree JP, Cortez E, et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clin Cancer Res. 2019;25:796-807.
42. Chen Z, Cheng K, Walton Z, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012;483:613-7.
43. The Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32:185-203.e13.
44. Kang R, Hou W, Zhang Q, et al. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. Cell Death Dis. 2014;5:e1480.
45. Shao DD, Xue W, Krall EB, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014;158:171-84.
46. Kapoor A, Yao W, Ying H, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014;158:185-97.
47. Rozengurt E, Eibl G. Crosstalk between KRAS, SRC and YAP signaling in pancreatic cancer: interactions leading to aggressive disease and drug resistance. Cancers. 2021;13:5126.
48. Drexler R, Küchler M, Wagner KC, et al. The clinical relevance of the Hippo pathway in pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol. 2021;147:373-91.
49. Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov. 2023;22:213-34.
50. Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRASG12C inhibition in cancer. N Engl J Med. 2021;384:2382-93.
51. Koga T, Suda K, Fujino T, et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments. J Thorac Oncol. 2021;16:1321-32.
52. Tanaka N, Lin JJ, Li C, et al. Clinical acquired resistance to KRASG12C inhibition through a novel KRAS Switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. 2021;11:1913-22.
53. Yaeger R, Mezzadra R, Sinopoli J, et al. Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer. Cancer Discov. 2023;13:41-55.
54. Little AS, Balmanno K, Sale MJ, et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal. 2011;4:ra17.
55. Ryan MB, Fece de la Cruz F, Phat S, et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition. Clin Cancer Res. 2020;26:1633-43.
56. Dilly J, Hoffman MT, Abbassi L, et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. 2024;14:2135-61.
57. Hofmann MH, Gmachl M, Ramharter J, et al. BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov. 2021;11:142-57.
58. Fedele C, Li S, Teng KW, et al. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. J Exp Med. 2021;218:e20201414.
59. Stites EC, Trampont PC, Ma Z, Ravichandran KS. Network analysis of oncogenic Ras activation in cancer. Science. 2007;318:463-7.
60. Sacher AG, Miller WH Jr, Patel MR, et al.; GO42144 Investigator Study group, GO42144 Investigator Study Group. Single-agent divarasib in patients with KRAS G12C-positive non-small cell lung cancer: long-term follow-up of a phase I study. J Clin Oncol. 2025;43:3249-53.
61. Murciano-Goroff YR, Hollebecque A, Heist RS, et al. Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study. Nat Commun. 2026;17:3834.
62. O’Reilly EM, Wolpin B, Pant S, et al. Abstract LB337: Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic pancreatic adenocarcinoma (mPDAC). Cancer Res. 2026;86:LB337.
63. O’Reilly EM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. 2026;395:325-37.
64. Lito P, Saborowski A, Yue J, et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 2014;25:697-710.
65. Gulay KCM, Zhang X, Pantazopoulou V, et al. Dual inhibition of KRASG12D and Pan-ERBB is synergistic in pancreatic ductal adenocarcinoma. Cancer Res. 2023;83:3001-12.
66. Ambrogio C, Köhler J, Zhou ZW, et al. KRAS dimerization impacts MEK inhibitor sensitivity and oncogenic activity of mutant KRAS. Cell. 2018;172:857-68.e15.
67. Chen PY, Muzumdar MD, Dorans KJ, et al. Adaptive and reversible resistance to kras inhibition in pancreatic cancer cells. Cancer Res. 2018;78:985-1002.
68. Turke AB, Song Y, Costa C, et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012;72:3228-37.
70. Alanazi FE, Alatawi Y, Alattar A, Alshaman R, Kotb AA, Hetta HF. Broad-spectrum RAS inhibition in pancreatic ductal adenocarcinoma: mechanistic advances and therapeutic promise. Pharmaceuticals. 2025;18:1788.
71. Suzuki S, Yonesaka K, Teramura T, et al. KRAS inhibitor resistance in MET-amplified KRASG12C non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms. Clin Cancer Res. 2021;27:5697-707.
72. Wu H, Zhu L, Zhang H, et al. Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma. PLoS One. 2015;10:e0116803.
73. Neuzillet C, Couvelard A, Tijeras-Raballand A, et al. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Histopathology. 2015;67:664-76.
74. Kim JH, Kim HS, Kim BJ, Lee J, Jang HJ. Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis. Oncotarget. 2017;8:73098-104.
75. Dong XD, Zhang M, Cai CY, et al. Overexpression of ABCB1 associated with the resistance to the KRAS-G12C specific inhibitor ARS-1620 in cancer cells. Front Pharmacol. 2022;13:843829.
76. Rijmers J, Retmana IA, Bui V, et al. ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure. Biomed Pharmacother. 2024;175:116720.
77. Tian H, Zhao D, Zhou Z, et al. SRC at the crossroads of KRAS inhibitor resistance: mechanisms and therapeutic opportunities. Cancer Lett. 2026;639:218194.
78. Brown WS, McDonald PC, Nemirovsky O, et al. Overcoming adaptive resistance to KRAS and MEK inhibitors by co-targeting mTORC1/2 complexes in pancreatic cancer. Cell Rep Med. 2020;1:100131.
79. O’Neil BH, Scott AJ, Ma WW, et al. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 2015;26:1923-9.
80. Bodoky G, Timcheva C, Spigel DR, et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs. 2012;30:1216-23.
81. Infante JR, Somer BG, Park JO, et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer. 2014;50:2072-81.
82. Lim K, Spencer KR, Safyan RA, et al. Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205). J Clin Oncol. 2024;42:4140.
83. Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014;39:91-100.
84. Khan N, Raza U, Ali Zaidi SA, et al. Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer. Cancer Biol Med. 2025;22:762-88.
85. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011;13:1016-23.
86. Egan DF, Shackelford DB, Mihaylova MM, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science. 2011;331:456-61.
87. Recouvreux MV, Grenier SF, Zhang Y, et al. Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma. Nat Cancer. 2024;5:100-13.
88. Rozeveld CN, Johnson KM, Zhang L, Razidlo GL. KRAS controls pancreatic cancer cell lipid metabolism and invasive potential through the lipase HSL. Cancer Res. 2020;80:4932-45.
89. Santana-Codina N, Roeth AA, Zhang Y, et al. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun. 2018;9:4945.
90. Ma J, Fu S, Tan J, et al. Mechanistic foundations of KRAS-driven tumor ecosystems: integrating crosstalk among immune, metabolic, microbial, and stromal microenvironment. Adv Sci. 2025;12:e02714.
91. Moore MJ, Hamm J, Dancey J, et al.; National Cancer Institute of Canada Clinical Trials Group. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21:3296-302.
92. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA; Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol. 2001;19:3447-55.
93. Hingorani SR, Zheng L, Bullock AJ, et al. HALO 202: Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2018;36:359-66.
94. Ramanathan RK, McDonough SL, Philip PA, et al. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J Clin Oncol. 2019;37:1062-9.
95. Van Cutsem E, Tempero MA, Sigal D, et al.; HALO 109-301 Investigators. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J Clin Oncol. 2020;38:3185-94.
96. Biondani G, Zeeberg K, Greco MR, et al. Extracellular matrix composition modulates PDAC parenchymal and stem cell plasticity and behavior through the secretome. FEBS J. 2018;285:2104-24.
97. Di Maggio F, Arumugam P, Delvecchio FR, et al. Pancreatic stellate cells regulate blood vessel density in the stroma of pancreatic ductal adenocarcinoma. Pancreatology. 2016;16:995-1004.
98. Wasko UN, Jiang J, Dalton TC, et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature. 2024;629:927-36.
99. McAndrews KM, Paradiso F, Stalnecker CA, et al. An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer. Sci Transl Med. 2025;17:eadt5511.
100. Rebelo R, Xavier CPR, Giovannetti E, Vasconcelos MH. Fibroblasts in pancreatic cancer: molecular and clinical perspectives. Trends Mol Med. 2023;29:439-53.
101. Geng X, Chen H, Zhao L, et al. Cancer-associated fibroblast (CAF) heterogeneity and targeting therapy of CAFs in pancreatic cancer. Front Cell Dev Biol. 2021;9:655152.
102. Pereira BA, Vennin C, Papanicolaou M, et al. CAF subpopulations: a new reservoir of stromal targets in pancreatic cancer. Trends Cancer. 2019;5:724-41.
103. Liu X, Baer JM, Stone ML, et al. Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy. Sci Transl Med. 2024;16:eado2402.
104. Jiang H, Hegde S, Knolhoff BL, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22:851-60.
105. Lander VE, Belle JI, Kingston NL, et al. Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade. Cancer Discov. 2022;12:2774-99.
106. Lencioni G, Gregori A, Toledo B, et al. Unravelling the complexities of resistance mechanism in pancreatic cancer: insights from in vitro and ex-vivo model systems. Semin Cancer Biol. 2024;106-7:217-33.
107. Mulero-Sánchez A, Bosma A, Visuvasam B, et al. CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer. J Exp Clin Cancer Res. 2026;45:60.
108. Liaki V, Barrambana S, Kostopoulou M, et al. A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proc Natl Acad Sci U S A. 2026;123:e2610708123.
109. Vahabi M, Comandatore A, Centra C, Blandino G, Morelli L, Giovannetti E. Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer. Semin Cancer Biol. 2023;97:50-67.
110. Haldar SD, Saj F, Hong SJ, et al. Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. Oncologist. 2026;31:oyag071.
111. Ghanwatkar Y, Mahto S, Chittipolu A, Ramanathan R, Shrestha P, Mahato RI. Dual inhibition of KRAS G12D and PI3K/BRD4 signaling overcomes therapeutic resistance in pancreatic cancer. Acta Biomater. 2026;212:637-54.
112. Yang K, Qin X, Wang Y, et al. Targeting class I HDACs suppresses oncogenic vulnerabilities and potentiates KRAS/MAPK pathway inhibitors in KRAS-mutant cancers. J Adv Res. 2026;In Press.
113. Xu X, Chen X, Xu R, et al. Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC. Nat Commun. 2026;17:3118.
114. Paulsohn MB, Frahnert KH, Schlösser D, et al. Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. Cell Death Dis. 2025;17:129.
115. Miyan J, Vudatha V, Cao L, et al. The combination of a BCL-xL PROTAC and an mTOR inhibitor sensitizes pancreatic ductal adenocarcinoma to KRASG12D inhibitor treatment. Cancers. 2026;18:920.
116. Park W, Kasi A, Spira AI, et al. Setidegrasib in advanced non-small-cell lung cancer and pancreatic cancer. N Engl J Med. 2026;394:1409-20.
117. Liang J, Wu J, Zhang Y, Wang H, Zheng Y, He Q. Systematic and precise interventions for KRAS-mutant cancers. Exp Hematol Oncol. 2026;15:33.
118. Arbour K, Punekar S, Garrido-Laguna I, et al. 652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Ann Oncol. 2023;34:S458.
119. Jiang J, Jiang L, Maldonato BJ, et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 2024;14:994-1017.
